Literature DB >> 8272181

Projected neurodegenerative disease mortality in the United States, 1990-2040.

D E Lilienfeld1, D P Perl.   

Abstract

Between 1990 and 2040, the United States elderly population is expected to grow from 31.6 to 68.1 million. In order to assess the implications of this increase on the mortality from neurodegenerative diseases in the United States, we used Census Bureau population estimates to formulate projections of the annual number of deaths from neurodegenerative diseases and from six comparison conditions (liver cirrhosis, colon cancer, lung cancer, cancer of the female breast, multiple sclerosis, and malignant melanoma), assuming that the United States disease-age-gender-race-specific death rates for 1985-1988 remain constant between 1990 and 2040. We find that neurodegenerative disease mortality increases by 119-231%, depending on the model of population growth used. For the 'middle' population growth model, the increase in annual neurodegenerative disease mortality is 166%. The major component of this increase is the rise in deaths attributed to dementia. For the six comparison diseases, the increases in mortality range from 52 (multiple sclerosis) to 130% (colon cancer). Given the current level of under ascertainment of neurodegenerative disease mortality and the conservative nature of the Census Bureau estimates of future population, it is likely that these projections are underestimates. The implications of these data are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8272181     DOI: 10.1159/000110320

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  13 in total

Review 1.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Identification of the first noncompetitive SARM1 inhibitors.

Authors:  Heather S Loring; Sangram S Parelkar; Santanu Mondal; Paul R Thompson
Journal:  Bioorg Med Chem       Date:  2020-07-17       Impact factor: 3.641

Review 3.  Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Authors:  L M Rubenstein; A DeLeo; E A Chrischilles
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey.

Authors:  L M Rubenstein; E A Chrischilles; M D Voelker
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

5.  Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991.

Authors:  P A Schulte; C A Burnett; M F Boeniger; J Johnson
Journal:  Am J Public Health       Date:  1996-09       Impact factor: 9.308

6.  Proteasome activity modulates amyloid toxicity.

Authors:  John Galvin; Elizabeth Curran; Francisco Arteaga; Alicia Goossens; Nicki Aubuchon-Endsley; Michael A McMurray; Jeffrey Moore; Kirk C Hansen; Heidi J Chial; Huntington Potter; Jeffrey L Brodsky; Christina M Coughlan
Journal:  FEMS Yeast Res       Date:  2022-03-09       Impact factor: 2.796

7.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 8.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole.

Authors:  Fatai Kunle Salawu
Journal:  Patient Prefer Adherence       Date:  2012-01-16       Impact factor: 2.711

Review 10.  Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.

Authors:  T Muir; M Zegarac
Journal:  Environ Health Perspect       Date:  2001-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.